Moderna, Inc. - Common Stock (MRNA)

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the company is currently navigating the "Keytruda Cliff"—the 2028 expiration of patents for its $30 billion-a-year blockbuster. While Merck has spent the last five [...]

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for their experimental mRNA cancer vaccine. The results, stemming from the Phase 2b KEYNOTE-942 trial, demonstrated that the combination of Moderna’

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based biotechnology giant is now aggressively shedding its image as a "one-hit wonder" vaccine maker. Following a volatile 2024 and 2025, the company has captured Wall [...]

Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year follow-up study of their skin cancer vaccine.